All In Biotech

Drug Trial Radar · NCT07922330

A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE-Asia)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Jan 4, 2027

Primary completion

Sep 15, 2028

Study completion Sep 15, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.

Conditions

  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus

Interventions

  • AZD6234Drug

    administered once weekly.

  • PlaceboDrug

    Matching placebo administered once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from baseline at Week 64Time frame: up to 64 weeks
  2. Number of participants achieving at Least a 5% Reduction in Body Weight From Baseline at Week 64Time frame: up to 64 weeks

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Bozhou, China

  • Research Site

    Cangzhou, China

  • Research Site

    Changzhou, China

  • Research Site

    Chongqing, China

  • Research Site

    Daqing, China

  • Research Site

    Ganzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Jiaxing, China

  • Research Site

    Jinan, China

  • Research Site

    Jinan, China

  • Research Site

    Liuzhou, China

  • Research Site

    Luoyang, China

  • Research Site

    Luzhou, China

  • Research Site

    Sanya, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenyang, China

  • Research Site

    Shiyan, China

  • Research Site

    Suzhou, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Xuancheng, China

  • Research Site

    Yuncheng, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Ansārinagar, India

  • Research Site

    Calicut, India

  • Research Site

    Kolkata, India

  • Research Site

    Ludhiana, India

  • Research Site

    Meerut, India

  • Research Site

    Surat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.